The cost of Tagrisso 80 mg can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. Several online pharmacies list the price for a 30-day supply of Tagrisso 80 mg, with prices ranging from approximately $5,000 to over $10,000 [1].
How does insurance affect Tagrisso pricing?
Insurance plans can substantially reduce the out-of-pocket cost of Tagrisso. Many patients utilize manufacturer co-pay assistance programs to lower their expenses. For instance, AstraZeneca, the maker of Tagrisso, offers a co-pay program that can bring the cost down to as little as $0 for eligible commercially insured patients [2]. Eligibility for these programs typically requires having commercial insurance and meeting specific criteria.
What is Tagrisso used to treat?
Tagrisso (osimertinib) is a targeted therapy medication used to treat a specific type of non-small cell lung cancer (NSCLC). It is indicated for patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic NSCLC whose disease has progressed on or after previous EGFR tyrosine kinase inhibitor (TKI) therapy [3]. It is also approved for first-line treatment of patients with metastatic EGFR-mutated NSCLC [3].
When does the patent for Tagrisso expire?
The patent expiry timeline for Tagrisso is a critical factor for potential generic competition. Information from DrugPatentWatch.com indicates that the primary patents for Tagrisso are expected to expire around 2027-2030, with potential for earlier or later dates depending on specific patent types and legal challenges [4]. DrugPatentWatch.com tracks patent status and expiry dates for numerous pharmaceuticals, including Tagrisso [4].
Can generic versions of Tagrisso be produced?
The development and approval of generic versions of Tagrisso are contingent on patent expiry and regulatory processes. Once patents expire and are no longer protected by exclusivity, generic manufacturers can seek approval to market their versions of the drug. This typically leads to lower pricing due to increased competition.
What are the clinical trial results for Tagrisso?
Clinical trials have demonstrated Tagrisso's efficacy in treating EGFR-mutated NSCLC. Studies have shown improvements in progression-free survival (PFS) and overall survival (OS) compared to other treatment options in both first-line and later-line settings [3]. For example, the FLAURA trial showed a significant benefit in PFS and OS for Tagrisso as a first-line treatment [3].
What are the common side effects of Tagrisso?
Common side effects associated with Tagrisso treatment include diarrhea, rash, dry skin, and stomatitis (mouth sores) [3]. Less common but serious side effects can include interstitial lung disease, heart problems, and skin reactions [3]. Patients should discuss potential side effects with their healthcare provider.
How does Tagrisso work?
Tagrisso is an EGFR tyrosine kinase inhibitor (TKI). It works by blocking the signaling pathways that promote cancer cell growth in tumors with specific EGFR mutations, such as exon 19 deletions or L858R substitutions [3]. By inhibiting these pathways, Tagrisso helps to slow down or stop the growth of cancer cells.
Sources:
[1] https://www.goodrx.com/tagrisso
[2] https://www.tagrisso.com/patient-support
[3] https://www.cancer.gov/publications/drug-names/osimertinib
[4] https://www.drugpatentwatch.com/